FSC approves Unipharm's Prospectus for Offering of Shares

FSC approves Unipharm's Prospectus for Offering of Shares

The Financial Supervision Commission (FSC) approved today Unipharm's prospectus for the public offering of shares on the Bulgarian Stock Exchange (BSE).

The issue of the company amounts to 500,000 leva (255,650 euros), divided in as many shares with 1 leva par value each and represents the registered capital of the company.

The issue and the company will be entered in FSC's public register.

Major shareholders in Unipharma include Ognyan Donev (38.37%,), Ventsislav Stoev (19.25%) and Ognyan Palaveev (12.89%) who is also the executive director of the company.

Unipharm's core activity is the production of high quality drugs, R&D of new technologies for the production of drugs, as well as distribution of drugs.

The company manufactures own products, as well as products under an assignment contract from its main partner Sopharma.

Facebook Коментари

Добави коментар

Екипът на Profit.bg Ви благодари, че използвате кирилица за вашите коментари.
В случай, че коментарът Ви съдържа нецензурни квалификации и лични нападки или обиди на расова, сексуална, етническа или верска основа, той ще бъде изтрит от модератора на сайта.

Абонирайте се за електронния
информационен бюлетин на Profit.bg